About Us
Mission Statement
Nelson Scientific Labs is a Maryland based biomedical research and consulting company founded in 2018. We discover, develop, and deliver biomarkers for exposure assessment, in vitro diagnostics and precision medicine. We acquire and study molecular profile data from diverse biological matrices using state-of-the-art analytic platforms for metabolomics, transcriptomics, and proteomics. We offer hope to cancer patients seeking early disease detection and health monitoring during curative radiation therapy. We aim to provide valuable solutions for personalized treatment and precision medicine that improve the cancer patient’s clinical outcome.
The mission of the company is to use personalized medicine approaches for improving clinical outcomes in cancer patients receiving curative radiation therapy. In order to attain this goal, we have developed strategic collaborations that combine inter-disciplinary programs including molecular profiling, clinical chemistry, bioinformatics and clinical care and treatment. Nelson has focused on biomarker panels for precision medicine in early detection of cancer and for prediction of radiation induced late effects and/or organ dysfunction.
Company Goals
At Nelson, we strive to break barriers in early cancer detection with kit-based susceptibility biomarkers for pancreatic cancer and late health effects of ionizing radiation exposure. These precision medicine tools will facilitate early decision-making, guide treatment options, and improve patient outcomes. The challenges in this pursuit require rigor, diligence, and expertise to overcome. To do so, we assembled a deep, experienced, engaged multi-disciplinary team dedicated towards improving and implementing novel study designd and cutting-edge analytics for biomarker exploration and development, according to biomarker qualification guidelines set forth by the U.S. Food and Drug Administration. We are one of the first Biotech. company focused on the use of multi-omics approaches for predicting ionizing radiation late health effects and early detection of pancreatic cancer. We are on our way to building a culture and a company focused on working collaboratively to save lives and improve health outcomes.
Notable Accomplishments:
- Early adopters of liquid chromatography-mass spectrometry metabolomics
- Foundational pioneers in biomarker discovery and validation for Delayed Effects of Acute Radiation Exposure (DEARE)
- Use of a blood-exosome-based liquid biopsy approach for building predictive algorithms for early detection of pancreatic cancer
Our Culture
At Nelson, our mission is to launch kit based biomarker assays as “In Vitro Diagnostics” with the goal of identifying sub-populations at risk of developing pancreatic cancer as well as those at risk of experiencing late effects following accidental or therapeutic exposure to ionizing radiation. With these goal, we are setting out to break barriers in the field of early detection. While we are aware that accomplishing these goals is challenging and will require rigor, diligence, and expertise; we believe that our team along with our strong academic partners can make a significant impact and help improve clinical outcomes.
We have a deep, experienced, engaged multi-disciplinary team dedicated towards improving and implementing novel study design and analytics for biomarker development. We have developed analytical pipelines for biomarker development in compliance with biomarker qualification guidelines. We are one of the first Biotech. company focused on the use of multi-omics approaches for the development of IVDs for predicting radiation late effects and early detection of pancreatic cancer We are on our way to building a culture and a company focused on working collaboratively to save lives and improve health outcomes.
Accomplishments of note: Early adopters of LC-MS metabolomics Foundational pioneers in biomarker discovery and validation for DEARE (Delayed Effects of Acute Radiation Exposure) Use a blood-exosome based liquid biopsy approach for building predictive algorithms for early detection of pancreatic cancer
Our Leaders
Bill J Singh, BA, MDBA
President and CEOMr. Singh is a retired Indian Navy Officer with an extensive background in government contracting and maritime consulting. He holds a BS in Political Science from Delhi University, India, and a Master's in Business Administration from Symbiosis Institute of Management in Pune, India. Mr. Singh founded Nelson Scientific Labs LLC in 2018 with a primary goal of translating tests developed in the laboratory to in vitro diagnostics for the health and medicine market. He currently serves as Nelson's President and Chief Executive Officer.
John B Tyburski, PhD, MPH
Principal ScientistDr. Tyburski is a public health researcher interested in developing biomarkers of exposure and late health effects. Working at the intersection of machine learning and epidemiology, he is developing methods to assess individual susceptibility to accidental and therapeutic radiation exposures. Dr. Tyburski holds a BS in Organismal Biology and a PhD in Physiology and Cell Biology from the University of Kansas as well as a Master of Public Health from the Johns Hopkins Bloomberg School of Public Health. Dr. Tyburski currently serves as Principal Scientist at Nelson Scientific Labs.
Our Advisors and Consultants
Dr. Anatoly Dritschilo, MD
Clinical advisorDr. Dritschilo currently serves as Chairman and Chief Exectutive Officer of Shuttle Pharmaceuticals, a company he co-founded in 2012. A radiation oncologist by training, Dr. Dritschilo holds a BS degree in Chemical Engineering from the University of Pennsylvania, a medical degree from the College of Medicine of New Jersey, and residency training from Harvard University's Joint Center of Radiation Therapy.
Amrita K Cheema, PhD
Scientific AdvisorDr. Cheema is a professor of Oncology and Biochemistry and co-director of the Waters Center of Innovation in Metabolomics at the Georgetown University Medical Center. Her research focuses on discovery and development of small-molecule biomarkers of exposure to ionizing radiation and adverse health outcomes of radiation therapy. Dr. Cheema's laboratory has also advanced molecular phenotyping with the development of reliable workflows and informatics tools.
Dr. Keith R. Unger, MD
Clinical ConsultantDr. Unger currently serves as the Interim Chief of Radiation Oncology and Director of the Gastrointestinal Cancer Service, as well as director of the residency training for the Department of Radiation Oncology at MedStar Georgetown University Hospital. He also fulfills the role of Acting Academic Chair of the Department of Radiation Medicine at Georgetown University School of Medicine, where he is a Professor. Dr. Unger's leadership extends to chairing the hospital's cancer committee.
Dr. Jill P. Smith, MD
Clinical ConsultantDr. Jill Smith is clinician scientist and Professor of Medicine at Georgetown University and the Lombardi Comprehensive Cancer Center. Dr. Smith also practices GI/Hepatology at the Washington DC Veterans Affairs Medical Center. As a clinical scientist, Dr. Smith's passion has been bench-to-bedside translational research. She has a basic science lab and is also conducting clinical trials in liver and pancreatic diseases.
Habtom Ressom, PhD
Computational ConsultantDr. Ressom is a Professor of in the Department of Oncology at Georgetown University and serves as the Scientific Director for OmicsCraft LLC in Washington, DC. He has many years of experience in developing algorithms using machine learning, fuzzy logic, and network-based methods for omics data analysis. His research interest focuses on identification of disease biomarkers using multi-omics approaches.
Shu Fu Chen, MS
Bioinformatics specialistMr. Chen is a Mathamatician and Bioinfomatition for Nelson Sci Lab. He utilize his background in computer science to developed innovative bioinformatic tools and statistics methods to solve complex “omics” problems. He is a full-stack developer with experience creating front-end web-based applications (using ReactJS) and back-end server solutions (using Python and Java).
Our Logistical Support Team
